The US Food and Drug Administration approvals of dupilumab (Dupixent, Regeneron/Sanofi) for adults and children with eosinophilic esophagitis (EoE) affirmed the safety and efficacy of the drug, which ...

Paris and Tarrytown, NY - March 2, 2018 - The U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application of Dupixent ® (dupilumab) as an add-on ...

TORONTO, Oct. 22, 2025 /CNW/ - Health Canada has approved Dupixent® (dupilumab injection) as an add-on maintenance treatment in adult patients with chronic obstructive pulmonary disease (COPD) ...

An anti-inflammation injectable drug called dupilumab can reduce mucus buildup and improve breathing among asthma patients, a new clinical trial says. Photo by Adobe Stock/HealthDay News An ...

Individuals with severe type 2 asthma and chronic rhinosinusitis with nasal polyps may benefit from the biologic treatment, dupilumab. A study on the efficacy of the biologic drug, dupilumab, found ...

This approval was based on findings from two clinical studies conducted in adult patients already receiving maximal standard-of-care inhaled therapy. The BOREAS and NOTUS studies showed a 30% and 34% ...

TORONTO, Sept. 12, 2024 /CNW/ - Health Canada has issued a Notice of Compliance (NOC) for DUPIXENT® (dupilumab injection) for the treatment of patients aged 1 year and older, weighing at least 15 kg, ...

Please provide your email address to receive an email when new articles are posted on . EVEREST represents the first head-to-head study of these biologics for CRSwNP. Differences between the biologics ...